HRP20170447T1 - Spiro-prstenasti spoj koji sadrži dušik i njegova upotreba u medicini - Google Patents
Spiro-prstenasti spoj koji sadrži dušik i njegova upotreba u medicini Download PDFInfo
- Publication number
- HRP20170447T1 HRP20170447T1 HRP20170447TT HRP20170447T HRP20170447T1 HR P20170447 T1 HRP20170447 T1 HR P20170447T1 HR P20170447T T HRP20170447T T HR P20170447TT HR P20170447 T HRP20170447 T HR P20170447T HR P20170447 T1 HRP20170447 T1 HR P20170447T1
- Authority
- HR
- Croatia
- Prior art keywords
- solvate
- pharmaceutically acceptable
- acceptable salt
- compound according
- image
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 58
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 46
- 239000012453 solvate Substances 0.000 claims 46
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 11
- 230000002265 prevention Effects 0.000 claims 10
- 102000015617 Janus Kinases Human genes 0.000 claims 7
- 108010024121 Janus Kinases Proteins 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000003449 preventive effect Effects 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 102000006503 Janus Kinase 2 Human genes 0.000 claims 3
- 108010019437 Janus Kinase 2 Proteins 0.000 claims 3
- 102000006500 Janus Kinase 3 Human genes 0.000 claims 3
- 108010019421 Janus Kinase 3 Proteins 0.000 claims 3
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 206010023332 keratitis Diseases 0.000 claims 3
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (52)
1. Spoj sljedeće opće formula [I]:
[image]
,
naznačen time što je Ra isti ili različiti i svaki od njih je:
(1) C1-6 alkil, ili
(2) atom halogena, n1 je cijeli broj, kojeg se bira između 0 do 4,
Rb je isti ili različiti i svaki od njih je:
(1) C1-6 alkil, ili
(2) atom halogena,
n2 je cijeli broj, kojeg se bira između 0 do 4,
m1 je cijeli broj, kojeg se bira između 0 do 3,
m2 je cijeli broj, kojeg se bira između 1 do 4,
Xa = Xb je:
(1) CH=CH,
(2) N=CH, ili
(3) CH=N,
X je:
(1) atom dušika, ili
(2) C-Rd, gdje je Rd atom vodika ili atom halogena,
Rc je skupina koju se bira između sljedećih (1) do (6):
(1) atom vodika,
(2) C1-6 alkil, koji može biti supstituiran s istim ili različitim 1 do 5 supstituenata, koje se bira između sljedećih skupina A,
(3) -C(=O)-Rc1,
(4) -C(=O)-O-Rc2,
(5) -C(=O)-NRc3Rc4
gdje su Rc1, Rc2, Rc3 i Rc4 isti ili različiti i svaki od njih je:
(i) atom vodika, ili
(ii) C1-6 alkil, koji može biti supstituiran s istim ili različitim 1 do 5 supstituenata, koje se bira između sljedećih skupina A, ili
(6) skupina formule:
[image]
,
gdje je Ya skupina koju se bira između sljedećih (i) do (iii):
(i) C1-6 alkilen,
(ii) -C(=O)-, ili
(iii) -C(=O)-O-,
prsten T je:
(i) C6-10 aril,
(ii) C3-10 cikloalkil, ili
(iii) zasićeni monoheterociklil, gdje zasićeni monoheterociklil ima 1 do 4 heteroatoma, koje se bira između atoma dušika, atoma kisika ili atoma sumpora, kao i atome ugljika, a broj atoma koji čine prsten je 3 do 7,
Rc5 je isti ili različiti i svaki od njih je:
(i) cijano, ili
(ii) nitro,
p je cijeli broj, kojeg se bira između 0 do 4,
skupina A je skupina koju čine:
(a) hidroksil,
(b) C1-6 alkoksi,
(c) cijano,
(d) C1-6 alkoksikarbonil,
(e) C1-6 alkilkarboniloksi, i
(f) C2-6 alkeniloksi, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što, u općoj formuli [I],
n1 je cijeli broj, kojeg se bira između 0 do 2,
n2 je cijeli broj, kojeg se bira između 0 do 2,
m1 je cijeli broj, kojeg se bira između 0 do 3,
m2 je cijeli broj, kojeg se bira između 1 do 3,
X je:
(1) atom dušika, ili
(2) C-Rd, gdje je Rd atom halogena,
Rc je skupina koju se bira između sljedećih (1) do (6):
(1) atom vodika,
(2) C1-6 alkil, supstituiran s jednim supstituentom, kojeg se bira između sljedećih skupina A,
(3) -C(=O)-Rc1,
(4) -C(=O)-O-Rc2,
(5) -C(=O)-NRc3Rc4
gdje je Rc1 C1-6 alkil, koji može biti supstituiran s jednim supstituentom, kojeg se bira između sljedećih skupina A,
Rc2 je C1-6 alkil,
Rc3 je C1-6 alkil, koji može biti supstituiran s jednim supstituentom, kojeg se bira između sljedećih skupina A,
Rc4 je
(i) atom vodika, ili
(ii) C1-6 alkil, ili
(6) skupina formule:
[image]
,
gdje je Ya skupina koju se bira između sljedećih (i) do (iii):
(i) C1-6 alkilen,
(ii) -C(=O)-, ili
(iii) -C(=O)-O-,
prsten T je:
(i) fenil,
(ii) C3-6 cikloalkil, ili
(iii) pirolidinil,
Rc5 je
(i) cijano, ili
(ii) nitro,
p je cijeli broj, kojeg se bira između 0 ili 1,
skupina A je skupina koju čine:
(a) hidroksil,
(b) C1-6 alkoksi,
(c) cijano,
(d) C1-6 alkoksikarbonil,
(e) C1-6 alkilkarboniloksi, i
(f) C2-6 alkeniloksi, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
3. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što je m1 cijeli broj 0 ili 1, a m2 je cijeli broj 1 ili 2, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
4. Spoj u skladu s patentnim zahtjevom 3, gdje je kombinacija (m1,m2) (1,2), naznačen time što je spoj opće formule [II]:
[image]
,
gdje svaki simbol ima isto značenje kao što je definirano u patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
5. Spoj u skladu s patentnim zahtjevom 3, gdje je kombinacija (m1,m2) (0,2), naznačen time što je spoj opće formule [III]:
[image]
,
gdje svaki simbol ima isto značenje kao što je definirano u patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
6. Spoj u skladu s patentnim zahtjevom 3, gdje je kombinacija (m1,m2) (0,1), naznačen time što je spoj opće formule [IV]:
[image]
,
gdje svaki simbol ima isto značenje kao što je definirano u patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
7. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što se kombinaciju (m1,m2) bira između (0,3), (2,1), (2,2) ili (3,2), ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je Xa = Xb CH=CH, a X je atom dušika, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
9. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što je kombinacija (n1,n2) (0,0), ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
10. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što je kombinacija (n1,n2) (1,0), ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
11. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što je kombinacija (n1,n2) (0,1), ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
12. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što je kombinacija (n1,n2) (2,0), ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
13. Spoj u skladu s bilo kojim od patentnog zahtjeva 1 ili 2, naznačen time što je kombinacija (n1,n2) (0,2), ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
14. Spoj u skladu s bilo kojim od patentnog zahtjeva 10 ili 12, naznačen time što je Ra metil ili atom fluora, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačen time što je Rc -C(=O)-Rc1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
16. Spoj u skladu s patentnim zahtjevom 15, naznačen time što je Rc1 C1-6 alkil, supstituiran s jednom hidroksilnom ili skupinom cijano, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
17. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačen time što je Rc -C(=O)-NRc3Rc4, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
18. Spoj u skladu s patentnim zahtjevom 17, naznačen time što je Rc3 C1-6 alkil, supstituiran s jednom skupinom cijano, a Rc4 je vodik, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
19. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između sljedećih kemijskih strukturnih formula:
[image]
[image]
[image]
[image]
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
20. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između sljedećih kemijskih strukturnih formula:
[image]
[image]
[image]
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
21. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
[image]
,
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
22. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
[image]
,
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
23. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
[image]
,
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
24. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
[image]
,
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
25. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
[image]
,
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
26. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
[image]
,
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
27. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
[image]
,
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
28. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat, kao i farmaceutski prihvatljivu podlogu.
29. Inhibitor Janus kinaze, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat.
30. Inhibitor Janus kinaze u skladu s patentnim zahtjevom 29, naznačen time što je Janus kinaza Janus kinaza 3.
31. Inhibitor Janus kinaze u skladu s patentnim zahtjevom 29, naznačen time što je Janus kinaza Janus kinaza 2.
32. Terapijsko ili preventivno sredstvo namijenjeno upotrebi u liječenju bolesti koju se bira iz skupine koju čine odbacivanje presađenog organa, reakcija presatka prema domaćinu nakon presađivanja, autoimuna bolest, alergijska bolest i kronična mijeloproliferativna bolest, naznačeno time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat.
33. Terapijsko ili preventivno sredstvo namijenjeno upotrebi u liječenju reumatoidnog artritisa, naznačeno time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
34. Terapijsko ili preventivno sredstvo namijenjeno upotrebi u liječenju psorijaze, naznačeno time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat.
35. Terapijsko ili preventivno sredstvo namijenjeno upotrebi u liječenju suhog keratokonjunktivitisa, naznačeno time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat.
36. Terapijsko ili preventivno sredstvo namijenjeno upotrebi u liječenju atopičnog dermatitisa, naznačeno time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat.
37. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, naznačen time što je namijenjen upotrebi u inhibiranju Janus kinaza.
38. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 37, naznačen time što je Janus kinaza Janus kinaza 3.
39. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 37, naznačen time što je Janus kinaza Janus kinaza 2.
40. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti koju se bira iz skupine koju čine odbacivanje presađenog organa, reakcija presatka prema domaćinu nakon presađivanja, autoimuna bolest, alergijske bolesti i kronična mijeloproliferativna bolest.
41. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju reumatoidnog artritisa.
42. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju psorijaze.
43. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju suhog keratokonjunktivitisa.
44. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju atopičnog dermatitisa.
45. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji inhibitora Janus kinaze.
46. Upotreba u skladu s patentnim zahtjevom 45, naznačena time što je Janus kinaza Janus kinaza 3.
47. Upotreba u skladu s patentnim zahtjevom 45, naznačena time što je Janus kinaza Janus kinaza 2.
48. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje bolesti koju se bira iz skupine koju čine odbacivanje presađenog organa, reakcija presatka prema domaćinu nakon presađivanja, autoimuna bolest, alergijske bolesti i kronična mijeloproliferativna bolest.
49. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje reumatoidnog artritisa.
50. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje psorijaze.
51. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje suhog keratokonjunktivitisa.
52. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 27, ili njegove farmaceutski prihvatljive soli ili njegovog solvata, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje atopičnog dermatitisa.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009179502 | 2009-07-31 | ||
US27413709P | 2009-08-13 | 2009-08-13 | |
PCT/JP2010/062873 WO2011013785A1 (ja) | 2009-07-31 | 2010-07-30 | 含窒素スピロ環化合物及びその医薬用途 |
EP10804531.1A EP2460806B1 (en) | 2009-07-31 | 2010-07-30 | Nitrogen-containing spiro-ring compound and medicinal use of same |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170447T1 true HRP20170447T1 (hr) | 2017-05-19 |
Family
ID=43529436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170447TT HRP20170447T1 (hr) | 2009-07-31 | 2017-03-20 | Spiro-prstenasti spoj koji sadrži dušik i njegova upotreba u medicini |
Country Status (31)
Country | Link |
---|---|
US (4) | US8609647B2 (hr) |
EP (3) | EP2460806B1 (hr) |
JP (8) | JP5520158B2 (hr) |
KR (1) | KR101773208B1 (hr) |
CN (1) | CN102510865B (hr) |
AR (1) | AR077497A1 (hr) |
AU (1) | AU2010278066B2 (hr) |
BR (1) | BR112012002157B1 (hr) |
CA (1) | CA2767899C (hr) |
CO (1) | CO6491052A2 (hr) |
CY (1) | CY1118747T1 (hr) |
DK (1) | DK2460806T3 (hr) |
ES (1) | ES2616705T3 (hr) |
HR (1) | HRP20170447T1 (hr) |
HU (1) | HUE033070T2 (hr) |
IL (1) | IL217048A (hr) |
LT (1) | LT2460806T (hr) |
ME (1) | ME02667B (hr) |
MX (1) | MX2012001313A (hr) |
MY (1) | MY163495A (hr) |
NZ (1) | NZ597994A (hr) |
PE (1) | PE20121276A1 (hr) |
PL (1) | PL2460806T3 (hr) |
PT (1) | PT2460806T (hr) |
RS (1) | RS55913B1 (hr) |
RU (1) | RU2630694C2 (hr) |
SG (1) | SG176918A1 (hr) |
SI (1) | SI2460806T1 (hr) |
TW (1) | TWI466885B (hr) |
WO (1) | WO2011013785A1 (hr) |
ZA (1) | ZA201200689B (hr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
CN103119045B (zh) * | 2010-08-20 | 2016-02-17 | 和记黄埔医药(上海)有限公司 | 吡咯并嘧啶化合物及其用途 |
PL2651417T3 (pl) | 2010-12-16 | 2017-08-31 | Calchan Limited | Pochodne pirolopirymidyny hamujące ASK1 |
JP6075736B2 (ja) | 2011-12-21 | 2017-02-08 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | ピロール−6員ヘテロアリール環誘導体、その合成法およびその医薬用途 |
US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
MY176525A (en) * | 2013-10-21 | 2020-08-13 | Japan Tobacco Inc | Therapeutic agent for ocular disease or prophylactic agent for ocular disease |
MX2016015613A (es) * | 2014-05-28 | 2017-04-13 | Astrazeneca Ab | Procesos para la preparacion de azd5363 e intermedios novedosos utilizados en el mismo. |
CA2991020A1 (en) * | 2015-07-07 | 2017-01-12 | Japan Tobacco Inc. | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
BR112018005771B1 (pt) * | 2015-09-24 | 2023-12-05 | Leo Pharma A/S | Uso de um composto |
CN108368091B (zh) * | 2015-09-25 | 2020-08-11 | 迪哲(江苏)医药有限公司 | 用于抑制jak的化合物和方法 |
PL3405197T3 (pl) | 2016-01-21 | 2024-02-12 | Leo Pharma A/S | Zastosowanie delgocytynibu w leczeniu przewlekłego wyprysku dłoni |
CA3040981A1 (en) * | 2016-11-23 | 2018-05-31 | Bing Liu | Preparation method for and intermediate of pyrrolo six-membered heteroaromatic ring derivative |
CN110325536A (zh) * | 2016-12-21 | 2019-10-11 | 日本烟草产业株式会社 | Janus激酶抑制剂的晶体形式 |
US11312728B2 (en) | 2016-12-21 | 2022-04-26 | Japan Tobacco Inc. | Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and co-crystals thereof |
AU2017384317C1 (en) | 2016-12-21 | 2022-06-30 | Japan Tobacco Inc. | PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF |
EP3571198B1 (en) * | 2017-01-20 | 2023-02-01 | LEO Pharma A/S | Bicyclic amines as jak kinase inhibitors |
EP3576743B1 (en) * | 2017-02-03 | 2023-01-18 | LEO Pharma A/S | 5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2 5]octane-8-carboxylic acid derivatives as jak kinase inhibitors |
CN111526874A (zh) * | 2017-10-10 | 2020-08-11 | 生物基因公司 | 用于制备螺环衍生物的方法 |
MX2020008106A (es) * | 2018-01-31 | 2020-09-25 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos. |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
SG11202110777XA (en) | 2019-05-15 | 2021-11-29 | Leo Pharma As | Treatment of cutaneous lupus erythematosus |
WO2021025129A1 (ja) * | 2019-08-07 | 2021-02-11 | ロート製薬株式会社 | 涙液分泌促進用眼科組成物 |
US20230101139A1 (en) * | 2019-12-27 | 2023-03-30 | Rohto Pharmaceutical Co., Ltd. | Aqueous Composition |
CN111606929B (zh) * | 2020-06-30 | 2023-07-07 | 中瀚(齐河县)生物医药科技有限公司 | 德高替尼的制备方法 |
CN111574540B (zh) * | 2020-06-30 | 2023-08-29 | 云南华派医药科技有限公司 | 一种德高替尼的制备方法 |
CN111560021B (zh) * | 2020-06-30 | 2023-05-26 | 上海鲲博玖瑞医药科技发展有限公司 | 一种德高替尼中间体及其制备方法 |
TW202227452A (zh) * | 2020-12-04 | 2022-07-16 | 大陸商廣州費米子科技有限責任公司 | 氮雜並環化合物、其製備方法、抑制酪氨酸激酶的方法、藥物組成物及其用途 |
TW202241439A (zh) * | 2020-12-29 | 2022-11-01 | 大陸商上海岸闊醫藥科技有限公司 | 治療與抗腫瘤劑相關的皮膚疾病或病症的試劑和方法 |
TW202406553A (zh) | 2022-04-20 | 2024-02-16 | 丹麥商理奧藥品公司 | 前額纖維化禿髮之治療 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9911612A (pt) | 1998-06-02 | 2001-02-06 | Osi Pharm Inc | Composições de pirrolo[2,3d]pirimidina e seus usos |
EP1087970B1 (en) * | 1998-06-19 | 2004-04-28 | Pfizer Products Inc. | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
EP1382339B1 (en) * | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
EA009789B1 (ru) * | 2002-07-05 | 2008-04-28 | Таргасепт, Инк. | N-арилдиазаспирациклические соединения и способы их получения и применения |
US20070275990A1 (en) | 2003-11-13 | 2007-11-29 | Ono Pharmaceutical Co., Ltd. | Heterocyclic Spiro Compound |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
US20090111805A1 (en) | 2005-02-24 | 2009-04-30 | Pfizer Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
ATE540948T1 (de) * | 2005-05-20 | 2012-01-15 | Vertex Pharma | Pyrrolopyridine als proteinkinasehemmer |
JP5071374B2 (ja) * | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ3阻害剤 |
ES2612196T3 (es) | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus |
GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
CA2635899A1 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
WO2008029237A2 (en) | 2006-09-05 | 2008-03-13 | Pfizer Products Inc. | Combination therapies for rheumatoid arthritis |
KR101122969B1 (ko) | 2006-12-22 | 2012-03-22 | 에프. 호프만-라 로슈 아게 | 스피로-피페리딘 유도체 |
TW200904437A (en) * | 2007-02-14 | 2009-02-01 | Janssen Pharmaceutica Nv | 2-aminopyrimidine modulators of the histamine H4 receptor |
JP2010523522A (ja) * | 2007-04-02 | 2010-07-15 | パラウ・フアルマ・ソシエダツド・アノニマ | Jak3阻害剤としてのピロロピリミジン誘導体 |
WO2009047255A1 (en) * | 2007-10-09 | 2009-04-16 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
CN102015708B (zh) | 2008-01-09 | 2014-03-26 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
CA2728559A1 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
CA2762174C (en) | 2009-05-22 | 2018-02-20 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
JP2018028525A (ja) * | 2016-08-15 | 2018-02-22 | 小野 信行 | イオンレーザーと重水素を利用した核融合炉 |
JP6229778B2 (ja) * | 2016-09-21 | 2017-11-15 | サミー株式会社 | 遊技機 |
-
2010
- 2010-07-22 TW TW99124110A patent/TWI466885B/zh active
- 2010-07-23 AR ARP100102681A patent/AR077497A1/es active IP Right Grant
- 2010-07-30 BR BR112012002157-5A patent/BR112012002157B1/pt active IP Right Grant
- 2010-07-30 RU RU2012106344A patent/RU2630694C2/ru active
- 2010-07-30 EP EP10804531.1A patent/EP2460806B1/en active Active
- 2010-07-30 HU HUE10804531A patent/HUE033070T2/hu unknown
- 2010-07-30 NZ NZ597994A patent/NZ597994A/xx unknown
- 2010-07-30 PE PE2012000097A patent/PE20121276A1/es active IP Right Grant
- 2010-07-30 WO PCT/JP2010/062873 patent/WO2011013785A1/ja active Application Filing
- 2010-07-30 CA CA2767899A patent/CA2767899C/en active Active
- 2010-07-30 SI SI201031426A patent/SI2460806T1/sl unknown
- 2010-07-30 MY MYPI2012000155A patent/MY163495A/en unknown
- 2010-07-30 DK DK10804531.1T patent/DK2460806T3/en active
- 2010-07-30 EP EP17150170.3A patent/EP3181570A1/en not_active Withdrawn
- 2010-07-30 LT LTEP10804531.1T patent/LT2460806T/lt unknown
- 2010-07-30 ES ES10804531.1T patent/ES2616705T3/es active Active
- 2010-07-30 EP EP21159390.0A patent/EP3858349A1/en active Pending
- 2010-07-30 SG SG2011094117A patent/SG176918A1/en unknown
- 2010-07-30 JP JP2010171260A patent/JP5520158B2/ja active Active
- 2010-07-30 US US12/847,025 patent/US8609647B2/en active Active
- 2010-07-30 MX MX2012001313A patent/MX2012001313A/es active IP Right Grant
- 2010-07-30 CN CN201080034068.1A patent/CN102510865B/zh active Active
- 2010-07-30 RS RS20170305A patent/RS55913B1/sr unknown
- 2010-07-30 PT PT108045311T patent/PT2460806T/pt unknown
- 2010-07-30 KR KR1020127001455A patent/KR101773208B1/ko active IP Right Grant
- 2010-07-30 ME MEP-2017-74A patent/ME02667B/me unknown
- 2010-07-30 AU AU2010278066A patent/AU2010278066B2/en active Active
- 2010-07-30 PL PL10804531T patent/PL2460806T3/pl unknown
-
2011
- 2011-12-18 IL IL217048A patent/IL217048A/en active IP Right Grant
-
2012
- 2012-01-18 CO CO12006869A patent/CO6491052A2/es active IP Right Grant
- 2012-01-27 ZA ZA2012/00689A patent/ZA201200689B/en unknown
-
2013
- 2013-11-12 US US14/077,446 patent/US20140187534A1/en not_active Abandoned
-
2014
- 2014-04-04 JP JP2014077850A patent/JP2014141516A/ja active Pending
-
2015
- 2015-11-17 JP JP2015224910A patent/JP2016029104A/ja not_active Ceased
-
2016
- 2016-11-02 JP JP2016214954A patent/JP2017019877A/ja not_active Ceased
-
2017
- 2017-03-20 HR HRP20170447TT patent/HRP20170447T1/hr unknown
- 2017-03-20 CY CY20171100348T patent/CY1118747T1/el unknown
-
2018
- 2018-02-21 JP JP2018028525A patent/JP2018111701A/ja not_active Ceased
-
2019
- 2019-12-04 JP JP2019219283A patent/JP2020033384A/ja not_active Withdrawn
-
2021
- 2021-09-06 JP JP2021144545A patent/JP2021183653A/ja not_active Withdrawn
- 2021-12-21 US US17/557,174 patent/US20230023377A1/en not_active Abandoned
-
2023
- 2023-05-05 US US18/143,720 patent/US20240150367A1/en active Pending
- 2023-08-07 JP JP2023128376A patent/JP2023138641A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170447T1 (hr) | Spiro-prstenasti spoj koji sadrži dušik i njegova upotreba u medicini | |
JP2011046700A5 (hr) | ||
HRP20200352T1 (hr) | Novi kondenzirani pirimidinski spoj ili njegova sol | |
RS52605B (en) | Benzoic Acids (1-Phenyl-2-pyridin-4-yl) -ETHYL ESTERS AS PHOSPHODIESTERASE INHIBITORS | |
AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
CO2017001603A2 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
RU2014147193A (ru) | Новые конденсированные пиримидиновые производные для ингибирования тирозинкиназной активности | |
WO2012156756A3 (en) | Macrocyclic compounds as protein kinase inhibitors | |
EA201001618A1 (ru) | Ингибиторы syk протеинкиназ | |
ES2710190T3 (es) | Derivados de 4-azaindol | |
RU2017125025A (ru) | Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk | |
HRP20221018T1 (hr) | Liječenje katapleksije | |
HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
EA201301319A1 (ru) | Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний | |
RU2015155585A (ru) | 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента | |
RS52126B (en) | AZABIFENYLAMINOBENZOIC ACID DERIVATIVES AS DYHydroOROTATE DEHYDROGENASE INHIBITORS (DHODH) | |
WO2011113802A3 (en) | Imidazopyridine and purine compounds, compositions and methods of use | |
EA201391558A1 (ru) | Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения | |
EA201071232A1 (ru) | Триазины как ингибиторы киназы pi3 и mtor | |
CA2936551A1 (en) | Substituted pyrrolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases | |
AR067599A1 (es) | Derivados de indazol sustituido activos como inhibidores de quinasa | |
NZ603643A (en) | Purinone derivative | |
RU2012125971A (ru) | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных | |
RU2008141239A (ru) | Соединения тетрагидропиридотиенопиримидина и способы их применения | |
RU2018121288A (ru) | Ингибиторы ионного канала, фармацевтические составы и применение |